- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00543504
Bevacizumab in Multiple Phase I Combinations
A Phase 1 Study of Bevacizumab in Combination With 1) Sunitinib, 2) Sorafenib, 3) Erlotinib and Cetuximab, 4) Trastuzumab and Lapatinib
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
The Study Drugs:
Bevacizumab (Avastin™) is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels
Sunitinib malate (SutentTM) is designed to block pathways that control important events such as the growth of blood vessels that are vital for the growth of cancer.
Sorafenib (NexavarTM) is designed to block the function of important proteins in cancer cells. These proteins, when active, are in part responsible for the abnormal growth and behavior of cancer cells.
Erlotinib hydrochloride (TarcevaTM) is designed to block the activity of a protein found on the surface of many tumor cells that may control tumor growth and survival. This may stop tumors from growing.
Cetuximab (ErbituxTM) is designed to prevent or slow down the growth of cancer cells by blocking proteins inside the cancer cell, called the epidermal growth factor receptor (EGFR).
Trastuzumab (HerceptinTM) is designed to prevent or slow down the growth of cancer cells by blocking proteins inside the cancer cell, called the Her2/neu receptor.
Lapatinib (TykerbTM) is designed to prevent or slow down the growth of cancer cells by blocking proteins inside the cancer cell, called the Her2/neu receptor and EGFR.
Study Drug Dose Level:
If you are found to be eligible to take part in this study, your doctor will decide which study drugs you will receive based on the disease type and on the drugs you have taken in the past.
Once it is decided which drugs you will receive, you will be enrolled into a group of about 3-6 participants that are receiving the same drug combination. The first group of participants will receive the lowest dose of the drug combination. The next group of participants will receive the next highest dose of the drug combination. The third group will receive an even higher dose than that. This process will continue until the study doctor finds the highest safe dose of the drug combination. The dose that you receive will depend on when you are enrolled in this study and the safety data that is available at that time. The dose that you receive may be lowered if you do not tolerate the study drug combination well.
Once the highest tolerated dose is found for each group, up to 10 more participants will be added to each group at that dose level.
The dose levels testing the study drug combination of bevacizumab with either sunitinib or sorafenib are now closed.
Study Drug Administration:
Avastin™ is given through a needle in your vein. The first infusion is over 90 minutes. The next infusion may be over 60 minutes if the first infusion was well tolerated. If you tolerate the second infusion well, the third infusion may be over 30 minutes. If you take trastuzumab and lapatinib with Avastin™, you will receive Avastin™ every 21 days. If you take cetuximab and erlotinib with Avastin™, you will receive Avastin™ every 14 days.
If you are assigned to take cetuximab and erlotinib, cetuximab will be given by vein once every week. The first time you receive cetuximab, it will be given over 2 hours. All other infusions will be given over 60 minutes. Erlotinib is taken by mouth every day during the 28-day study cycle. You should take erlotinib on an empty stomach either 1 hour before eating or 2 hours after eating.
If you are assigned to take trastuzumab and lapatinib, trastuzumab will be given by vein once every 21-day study cycle. The first infusion will be over 90 minutes. If you handle the infusion well, each additional infusion will be over 30 minutes Lapatinib will be taken by mouth every day for 21 days. You should take lapatinib on an empty stomach either 1 hour before eating or 2 hours after eating.
Study Visits:
Avastin, cetuximab, and erlotinib:
During Cycle 1, you will have a study visit during Weeks 1 and 2. During Cycles 2 and beyond, you will have a study visit during Week 1. At these visits, you will have a physical exam, and blood (about 1 tablespoon) will be drawn for routine tests. If the routine urine test done at screening had abnormal results, urine may be collected for additional routine tests during the study. After 2 cycles, you will have the physical exam every 1-2 months.
Every week, you will have blood drawn (about 2 teaspoons) for routine tests.
During Week 1 of all cycles, you will have urine collected for routine tests.
After every 2 cycles, you will have a CT or MRI scan to check the status of the disease. After 6 months (6 cycles) of study drug treatment, you will have the CT or MRI scan every 2-4 cycles.
Avastin, trastuzumab, and lapatinib:
During Cycle 1, you will have a study visit during Weeks 1 and 2. During Cycles 2 and beyond, you will have a study visit during Week 1. At these visits, you will have a physical exam, and blood (about 1 tablespoon) will be drawn for routine tests. If the routine urine test done at screening had abnormal results, urine may be collected for additional routine tests during the study. After 2 cycles, you will have the physical exam every 1-2 months.
During Week 1 of all cycles, you will have urine collected for routine tests.
After every 2 cycles, you will have a CT or MRI scan to check the status of the disease. After 6 months (8 cycles) of study drug treatment, you will have the CT or MRI scan every 2-4 cycles.
Length of Study:
You may remain on study for as long as you are benefitting. You will be taken off study if the disease gets worse or intolerable side effects occur.
This is an investigational study. Avastin™, erlotinib, cetuximab, trastuzumab, and lapatinib are all FDA approved and commercially available. Avastin™ is FDA approved for the treatment of colorectal cancer and lung cancer. Erlotinib is FDA approved for the treatment of lung cancer and pancreatic cancer. Cetuximab is FDA approved for the treatment of colorectal cancer and cancer of the head and neck. Trastuzumab is FDA approved for the treatment of breast cancer. Lapatinib is FDA approved for the treatment of breast cancer. The use of these drugs together is investigational and authorized for use in research only.
Up to 354 patients will take part in this study. All will be enrolled at M. D. Anderson.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- University of Texas MD Anderson Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients with advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or have no standard therapy that induces a CR rate of at least 10% or improves survival by at least three months.
- Patients must be three weeks from prior cytotoxic therapy; if they have recovered their blood counts to eligibility levels sooner and have no mucositis or other acute toxicities, they may be treated earlier but no sooner than two weeks after their last chemotherapy. Patients must be two weeks or five half lives from biologic therapy, whichever is shorter.
- ECOG performance status </= 2 (Karnofsky >/= 60%).
- Patients must have normal organ and marrow function defined as: absolute neutrophil count >/= 1,000/mL; platelets >/=75,000/mL; creatinine </= 3 X ULN; total bilirubin </= 2.0; ALT(SGPT) </= 3 X ULN; Exception for patients with liver metastasis: total bilirubin </= 3 x ULN; ALT(SGPT) </= 5 X ULN. Exception for the bevacizumab + erlotinib + cetuximab arm and the bevacizumab + trastuzumab + lapatinib arm: no minimum absolute neutrophil count or platelet count.
- The effects of bevacizumab on the developing human fetus are unknown. Angiogenesis is of critical importance to fetal development, and bevacizumab is likely to have adverse consequences in terms of fetal development. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days after the last dose.
- Ability to understand and the willingness to sign a written informed consent document.
- Life expectancy of at least 3 months.
- Patients with a prior DVT/PE are eligible for treatment if they are receiving or have finished receiving appropriate anticoagulation therapy.
Exclusion Criteria:
- Patients with hemoptysis within 28 days prior to entering the study.
- Patients with clinically significant unexplained bleeding within 28 days prior to entering the study.
- Uncontrolled systemic vascular hypertension (Systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg on medication).
- Patients with clinically significant cardiovascular disease: history of CVA within 6 months, myocardial infarction or unstable angina within 6 months, or unstable angina pectoris.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring parenteral antibiotics on Day 1.
- Pregnant or lactating women.
- History of hypersensitivity to bevacizumab, murine products, or any component of the formulation.
- (For patients on the sunitinib treatment arm and the trastuzumab/lapatinib treatment arm only) Left ventricular ejection fraction of less than 50% unless the patient is receiving an angiotensin-converting enzyme (ACE) inhibitor / angiotensin receptor blocker (ARB) and a beta-blocker.
- (For sorafenib treatment arm only) Hypersensitivity to sorafenib or any component of the formulation.
- (For erlotinib and cetuximab treatment arm only) History of hypersensitivity to erlotinib or any component of the formulation.
- (For erlotinib and cetuximab treatment arm only) History of hypersensitivity to cetuximab, murine products, or any component of the formulation.
- (For trastuzumab and lapatinib treatment arm only) History of hypersensitivity to trastuzumab, Chinese hamster ovary cell proteins, or any component of the formulation.
- (For trastuzumab and lapatinib treatment arm only) History of hypersensitivity to lapatinib or any component of the formulation.
- Patients with clinically significant gastrointestinal bleeding within 28 days prior to entering the study.
- Patients with hemorrhagic brain metastases.
- Patients with prior abdominal surgery within 30 days prior to entering the study.
- (For patients on the sunitinib treatment arm and the trastuzumab/lapatinib treatment arm only) Left ventricular ejection fraction of less than 50%, unless the patient is receiving an angiotensin-converting enzyme (ACE) inhibitor / angiotensin receptor blocker (ARB) and a beta-blocker.
- (For patients on the sunitinib treatment arm and the trastuzumab/lapatinib treatment arm only) QTc prolongation, defined as greater than 440 milliseconds for males, and greater than 460 milliseconds for females.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Bevacizumab + Sunitinib
Arm 1: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Sunitinib 12.5 mg orally daily for 4 weeks, then 2 weeks off.
|
2.5 mg/kg By Vein Over 90 Minutes.
Andere namen:
12.5 mg orally daily for 4 weeks, then 2 weeks off.
Andere namen:
|
Experimenteel: Bevacizumab + Sorafenib
Arm 2: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Sorafenib 200 mg by mouth daily for 28 Days
|
2.5 mg/kg By Vein Over 90 Minutes.
Andere namen:
200 mg By Mouth Daily for 28 Days
Andere namen:
|
Experimenteel: Bevacizumab + Erlotinib + Cetuximab
Arm 3: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Erlotinib 50 mg By Mouth Daily for 28 Days + Cetuximab loading dose 100 mg/m² IV and maintenance 75 mg/m² on Days 1, 8, 15, 22.
|
2.5 mg/kg By Vein Over 90 Minutes.
Andere namen:
50 mg By Mouth Daily for 28 Days.
Andere namen:
Loading 100 mg/m² by vein and Maintenance 75 mg/m² by vein on Days 1, 8, 15, 22
|
Experimenteel: Bevacizumab + Trastuzumab + Lapatinib
Arm 4: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Trastuzumab loading dose 2 mg/kg IV then maintenance dose 1 mg/kg IV on Day 1 + Lapatinib 250 mg By Mouth Daily for 21 Days.
|
2.5 mg/kg By Vein Over 90 Minutes.
Andere namen:
Loading 2 mg/kg by vein then Maintenance 1 mg/kg by vein on Day 1
Andere namen:
250 mg By Mouth Daily for 21 Days.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Maximum Tolerable Dose (MTD) of Avastin in combination with 4 other study drug/drug combinations
Tijdsspanne: 28 days
|
MTD defined by Dose Limiting Toxicity in first 28 day cycle (induction phase)
|
28 days
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Funda Meric-Bernstam, MD, M.D. Anderson Cancer Center
Publicaties en nuttige links
Algemene publicaties
- Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol. 2020 Apr 20;9:7. doi: 10.1186/s40164-020-00159-1. eCollection 2020.
- Falchook GS, Moulder SL, Wheler JJ, Jiang Y, Bastida CC, Kurzrock R. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Ann Oncol. 2013 Dec;24(12):3004-11. doi: 10.1093/annonc/mdt395. Epub 2013 Oct 24.
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Enzymremmers
- Antineoplastische middelen
- Antineoplastische middelen, immunologisch
- Angiogenese-remmers
- Angiogenese modulerende middelen
- Groei stoffen
- Groeiremmers
- Proteïnekinaseremmers
- Trastuzumab
- Erlotinibhydrochloride
- Sorafenib
- Sunitinib
- Bevacizumab
- Cetuximab
- Lapatinib
Andere studie-ID-nummers
- 2006-0638
- NCI-2012-01552 (Register-ID: NCI CTRP)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Geavanceerde kanker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
Extremity MedicalWervingArtrose | Inflammatoire artritis | Carpaal Tunnel Syndroom (CTS) | Posttraumatische artritis | Scapholunate geavanceerde instorting (SLAC) | Scapholunaat Crystalline Advanced Collapse (SCAC) | Scaphoid, Trapezium en Trapezoid Advanced Collapse (STTAC) | Ziekte van Kienbock bij volwassenen | Radiale... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Advanced BionicsVoltooidErnstig tot zeer ernstig gehoorverlies | bij volwassen gebruikers van Advanced Bionics HiResolution™ Bionic Ear SystemVerenigde Staten
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)WervingAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
Klinische onderzoeken op Bevacizumab
-
National Cancer Institute (NCI)Actief, niet wervendRecidiverend eileidercarcinoom | Recidiverend ovariumcarcinoom | Recidiverend primair peritoneaal carcinoom | Ovarieel heldercellig cystadenocarcinoom | Ovarieel endometrioïde adenocarcinoom | Ovarieel sereus cystadenocarcinoom | Endometrium Clear Cell Adenocarcinoom | Endometrium sereus adenocarcinoom en andere voorwaardenVerenigde Staten
-
National Cancer Institute (NCI)VoltooidCervicaal adenocarcinoom | Cervicaal adenosquameus carcinoom | Cervicaal plaveiselcelcarcinoom, niet anders gespecificeerd | Stadium IVA Baarmoederhalskanker AJCC v6 en v7 | Recidiverend cervicaal carcinoom | Stadium IV Baarmoederhalskanker AJCC v6 en v7 | Stadium IVB Baarmoederhalskanker AJCC...Verenigde Staten
-
National Cancer Institute (NCI)NRG OncologyVoltooidBevacizumab met of zonder trebananib bij de behandeling van patiënten met terugkerende hersentumorenGlioblastoom | Gliosarcoom | Recidiverend glioblastoom | Oligodendroglioom | Gigantisch celglioblastoom | Terugkerend hersenneoplasmaVerenigde Staten, Canada
-
M.D. Anderson Cancer CenterWervingStadium IB Hepatocellulair carcinoom AJCC v8 | Stadium II hepatocellulair carcinoom AJCC v8 | Resectabel hepatocellulair carcinoom | Stadium I hepatocellulair carcinoom AJCC v8 | Stadium IA Hepatocellulair carcinoom AJCC v8Verenigde Staten
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WervingRecidiverend eileidercarcinoom | Recidiverend ovariumcarcinoom | Recidiverend primair peritoneaal carcinoom | Ovarieel endometrioïde adenocarcinoom | Ovarieel heldercellig adenocarcinoom | Eileider Clear Cell Adenocarcinoom | Endometrioïde adenocarcinoom van de eileider | Eileider Sereus Adenocarcinoom en andere voorwaardenVerenigde Staten
-
National Cancer Institute (NCI)Actief, niet wervendOvarieel endometrioïde adenocarcinoom | Primair peritoneaal hooggradig sereus adenocarcinoom | Endometrioïde adenocarcinoom van de eileider | Platina-resistent eileidercarcinoom | Platina-resistent primair peritoneaal carcinoom | Hoogwaardig sereus adenocarcinoom van de eierstokken | Platina-resistent... en andere voorwaardenVerenigde Staten, Canada
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsVoltooidRecidiverend eileidercarcinoom | Recidiverend ovariumcarcinoom | Recidiverend primair peritoneaal carcinoom | Platina-resistent eileidercarcinoom | Platina-resistent primair peritoneaal carcinoom | Platina-resistent ovariumcarcinoom | Refractair ovariumcarcinoom | Refractair eileidercarcinoom | Refractair...Verenigde Staten
-
Mayo ClinicNational Cancer Institute (NCI)Actief, niet wervendKwaadaardig solide neoplasma | Ovarieel endometrioïde adenocarcinoom | Ovarium ongedifferentieerd carcinoom | Cervicaal adenocarcinoom | Cervicaal adenosquameus carcinoom | Kwaadaardig peritoneaal neoplasma | Endometrium Clear Cell Adenocarcinoom | Endometrium Endometrioïde adenocarcinoom | Endometrium... en andere voorwaardenVerenigde Staten
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsWervingRecidiverend eileidercarcinoom | Recidiverend ovariumcarcinoom | Recidiverend primair peritoneaal carcinoom | Recidiverend endometrium sereus adenocarcinoom | Ovarieel heldercellig adenocarcinoom | Recidiverend platinaresistent ovariumcarcinoom | Platinagevoelig ovariumcarcinoom | Recidiverend endometrioïde... en andere voorwaardenVerenigde Staten
-
National Cancer Institute (NCI)Actief, niet wervendStadium IV huidmelanoom AJCC v6 en v7 | Stadium IIIC Cutaan Melanoom AJCC v7 | Inoperabel melanoomVerenigde Staten